Efficacy and Safety of Platelet Inhibitors

Ornella Binazon1, Audrey Dubois-Gauche2, Radu M Nanau3, Manuela G Neuman4

1In Vitro Drug Safety and Biotechnology, Toronto and Faculty of Pharmacy, University Paris Descartes, Paris
2In Vitro drug Safety and Biotechnology, Toronto and Faculty of Pharmacy, University Paul Sabatier, Toulouse, France
3In Vitro drug Safety and Biotechnology, and Department of Pharmacology, Faculty Medicine, University of Toronto, Toronto
4In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto


Ischemic heart disease is the second leading cause of death in the world. The proportion of deaths resulting from this condition has decreased in the last two decades, mainly as a result of improved primary and secondary prevention of cardiovascular events, as well as the development of patient awareness and medical and pharmacological management. The purpose of the present review is to analyze pathophysiological events leading to platelet involvement in cardiovascular thrombosis, as well as the role of pharmacogenetics in modulating the risk of cardiovascular disorders. The present work was performed using a PubMed search with combinations of key words relevant to the subject in both English and French. In addition to the pharmacokinetic and pharmacodynamic characteristics of platelet inhibitors, this work reviews the efficacy and adverse events observed during the clinical trials with these drugs. This review further summarizes possible therapeutic drug monitoring strategies for antiplatelet drugs. The novelty of this work is the description of the lymphocyte toxicity assay as a specific method of diagnosing and predicting possible idiosyncratic adverse events attributable to antiplatelet medication.

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

J Pharm Pharm Sci, 16 (1): 1-39, 2013

Full Text:


DOI: http://dx.doi.org/10.18433/J3MP4Z